Additionally, FLT3 inhibitors may modulate BCL-XL and MCL-1 expression, increasing the dependence of tumor cells on BCL-2 and potentially enhancing the efficacy of venetoclax [12, 13]. The gene discussed is BCL2; the disease is neoplasm.